BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Doxorubicin
,
rs7903146
,
FXYD4
,
glucose metabolic process
,
Arthritis
,
Retina
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ERK%201
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for ERK%201
Explore Curated Studies Results
Literature
Most Relevant Literature
Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in…
Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in pl…
The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and …
Integrated analysis of mRNA and microRNA expression pattern reveals differential transcriptome signa…
Gene Expression in Bronchial Epithelial Cell Responses to Vanadium Exposure.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic …
ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelia…
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
Study of ASTX029 in Subjects With Advanced Solid Tumors
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ